Saturday 17 October 2026 Export CHRS’s income statement to Excel — free account

Coherus Oncology, Inc.

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%

Follow CHRS

Alert me

Market cap: $165.3M
P/E: 0.0×
Fwd P/E: −1.4×
Dividend yield: —
F-score: 6/9
Altman Z: −8.83
Beneish M: −3.44
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 25.45%

Capital & Financial Ratios $m

Market Cap 165.32

Revenue 50.94

Net Income (132.13)

Free Cash Flow (186.03)

Net Debt (68.06)

Current Ratio 1.77

Debt/Equity 0.61

P/E ratio 0.00

Fwd P/E (1.41)

P/S ratio 3.04

P/B ratio 2.54

Past 5Y EPS Growth (2.46%)

This Y EPS Growth 43.24%

Next Y EPS Growth 13.97%

Next Y revenue growth 44.20%

Next 5Y EPS Growth 28.76%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 40.29%

10-year low 10-year high

P/B against its own 10 years 9.20%

10-year low 10-year high

EV/Sales against its own 10 years 56.62%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	118	126	172	105
Receivables	261	122	18	14
Inventory	63	4	3	6
Other	11	10	6	5
	476	342	207	134

	2023	2024	2025	Q'26
Payables	35	28	10	13
ST’ Debt	—	—	—	—
Other	—	—	—	—
	332	283	140	76

Compound Annual Growth %

	10y	5y	3y
Sales	3.09%	(38.41%)	(41.54%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	4.91%	0.00%
Book Value	0.00%	(26.32%)	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	12	14	—	—	—
’25	8	10	12	13	42
’24	2	10	6	8	26
’23	32	59	75	92	257
’22	60	60	45	45	211
’21	83	88	83	73	327
’20	116	136	114	110	476

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(58)	(62)	—	—	—
’25	(26)	(47)	(46)	(20)	(139)
’24	(47)	60	(62)	29	(20)
’23	(69)	(39)	(54)	(13)	(175)
’22	(54)	(50)	(37)	(100)	(241)
’21	1	0	14	(52)	(37)
’20	13	60	47	33	154

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(58)	(62)	—	—	—
’25	(26)	(47)	(46)	(20)	(139)
’24	(47)	60	(62)	29	(20)
’23	(69)	(39)	(55)	(13)	(175)
’22	(55)	(51)	(38)	(100)	(243)
’21	1	(1)	13	(53)	(39)
’20	12	58	45	32	147

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.28)	(0.13)	—	—	—
’25	(0.49)	2.57	(0.31)	(0.31)	1.43
’24	0.83	(0.11)	(0.09)	(0.44)	0.25
’23	(0.96)	(0.49)	(0.41)	(0.71)	(2.53)
’22	(1.24)	(0.65)	(1.11)	(0.76)	(3.76)
’21	(2.37)	(0.40)	(0.49)	(0.60)	(3.81)
’20	0.48	0.70	0.33	0.12	1.62

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	12.04	8.05	8.39	8.32	10.86	12.21	5.58	1.43	0.66	0.71	Analyst estimates 2026–2028 Powerpack
	High	31.98	29.59	20.66	23.91	23.03	22.22	16.48	10.99	3.70	1.89
People
People	Employees	152	122	232	291	317	332	359	306	306	147
	Revenue/emp, $m	1.25	0.01	0.00	1.22	1.50	0.98	0.59	0.84	0.09	0.29
Income, $m
Income, $m	Revenue	190	2	—	356	476	327	211	257	26	42
	Gross margin, %	100.00	100.00	0.00	95.20	92.08	82.36	66.79	38.19	66.93	67.24
	EBT	(128)	(238)	(209)	93	136	(287)	(292)	(238)	(215)	(183)
	EBT margin, %	(67.22)	(15,314.01)	0.00	26.06	28.52	(87.92)	(138.24)	(92.62)	(816.23)	(434.23)
	Net income	(128)	(238)	(209)	90	132	(287)	(292)	(238)	29	168
	Depreciation	3	3	3	3	3	3	4	4	5	4
Per share, $
Per share, $	Revenue	4.54	0.03	0.00	5.11	6.66	4.33	2.72	2.73	0.23	0.36
	Earnings	(3.04)	(4.48)	(3.22)	1.29	1.85	(3.81)	(3.76)	(2.53)	0.25	1.43
	Cash flow	(6.03)	(3.77)	(2.45)	0.41	2.16	(0.50)	(3.11)	(1.86)	(0.18)	(1.18)
	Capex	(0.16)	(0.09)	(0.01)	(0.03)	(0.10)	(0.02)	(0.03)	0.00	0.00	0.00
	Free cash flow	(6.18)	(3.86)	(2.46)	0.38	2.06	(0.51)	(3.13)	(1.86)	(0.18)	(1.18)
	Book value	0.46	0.57	(0.59)	1.51	3.93	1.30	(1.77)	(2.05)	(1.15)	0.52
	Shares, m	42	53	65	70	71	75	78	94	115	117
Valuation, ×
Valuation, ×	P/E	0.00	0.00	—	14.07	9.39	0.00	0.00	0.00	5.11	0.97
	P/S	6.17	211.43	—	3.52	2.61	3.69	3.13	1.15	5.99	3.94
	P/B	60.64	16.62	—	11.93	4.42	12.32	0.00	0.00	0.00	2.73
	EV/Sales	6.04	200.86	—	3.53	2.33	4.04	4.47	2.55	17.89	4.89
	EV/FCF	(4.43)	(2.35)	—	47.41	7.54	(34.10)	(3.88)	(3.73)	(22.08)	(1.48)
Cash, $m
Cash, $m	Operating cash flow	(253)	(200)	(159)	28	154	(37)	(241)	(175)	(20)	(139)
	Capex	(7)	(5)	(1)	(2)	(7)	(1)	(2)	0	—	—
	Free cash flow	(259)	(205)	(160)	27	147	(39)	(243)	(175)	(20)	(139)
Balance, $m
Balance, $m	Working capital	105	117	51	228	622	437	243	144	59	66
	Total debt	100	102	103	178	404	408	471	473	265	37
	Net debt	(25)	(25)	31	1	(137)	(9)	279	356	139	(135)
	Shareholders’ equity	19	31	(39)	105	281	98	(137)	(193)	(132)	61
Returns, %
Returns, %	ROA	(65.16)	(139.65)	(159.75)	35.34	21.15	(37.75)	(50.29)	(42.85)	5.29	47.54
	ROIC	0.00	(2,805.20)	0.00	63.58	67.92	(185.69)	(113.10)	(78.30)	(1,795.44)	0.00
	ROE	(2,049.69)	(954.80)	5,197.10	269.68	68.49	(151.62)	1,470.09	143.81	(17.52)	(473.47)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ORMP Oramed Pharmaceuticals Inc.	$173.9M	1.0×	— (loss-making)	+193.26% (above 0%: growing)	+493.75% (above 0%: growing)	+94.29% (above 0%: growing)	0.65%	0.00%	Compare
WHWK Whitehawk Therapeutics, Inc.	$173.3M	— (loss-making)	— (loss-making)	+33.48% (above 0%: growing)	n/m	+72.57% (above 0%: growing)	89.36%	0.00%	Compare
DTIL Precision BioSciences, Inc.	$170.3M	— (loss-making)	— (loss-making)	+37,272.41% (above 0%: growing)	n/m	+33.73% (above 0%: growing)	100.00%	0.00%	Compare
CHRS Coherus Oncology, Inc.	$165.3M	— (loss-making)	— (loss-making)	+39.53% (above 0%: growing)	n/m	−33.15% (below 0%: shrinking)	70.35%	(225.98%)
IPHA Innate Pharma S.A. Sponsored ADR	$165.3M	— (loss-making)	—	+246.29% (above 0%: growing)	+106.08% (above 0%: growing)	−929.03% (below 0%: shrinking)	0.00%	0.00%	Compare
VRXA Veraxa Biotech AG	$162.5M	—	—	—	—	—	—	—	Compare
CMPX Compass Therapeutics, Inc.	$161.5M	— (loss-making)	— (loss-making)	—	n/m	−26.05% (below 0%: shrinking)	100.00%	0.00%	Compare
ADAG Adagene Inc. Sponsored ADR	$161.1M	— (loss-making)	— (loss-making)	—	—	−11.08% (below 0%: shrinking)	—	—	Compare
MDWD MediWound Ltd.	$157.6M	— (loss-making)	— (loss-making)	−45.83% (below 0%: shrinking)	n/m	−49.90% (below 0%: shrinking)	10.90%	(305.89%)	Compare
Median of peers	$163.9M	—	—	+193.26%	—	−11.08%	50.13%	0.00%

All 614 Biotechnology stocks →

Coherus Oncology, Inc. (CHRS) key facts

Coherus Oncology, Inc. (CHRS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CHRS traded at $1.00, a market capitalization of $165.3 million.
Return on equity was −473.5% and debt-to-equity 0.61.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −8.83 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.